SciTropin A

SciTropin A





Cosma Medical


Cosma Medical
Concise Prescribing Info
Growth disturbance due to insufficient secretion of growth hormone, associated w/ Turner syndrome, or in short childn [current height standard deviation score (SDS) <-2.5 & parenteral adjusted <-1] born small for gestational age, w/ a birth wt &/or length below -2 standard deviation, who fail to show catch-up growth by ≥4 yr.
Dosage/Direction for Use
Childn Growth disturbance due to insufficient secretion of growth hormone 0.025-0.035 mg/kg or 0.7-1 mg/m2 daily. Turner syndrome 0.045-0.050 mg/kg or 1.4 mg/m2 daily. Short childn born small for gestational age (SGA) 0.035 mg/kg or 1 mg/m2 until final height is reached.
Hypersensitivity. Evidence of tumour activity, childn w/ closed epiphyses; PWS & a severe resp disorder or obesity, acute critical illness suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute resp failure. Childn <2 yr (premature babies & neonates).
Special Precautions
Observe for evidence of glucose intolerance. Test thyroid function after starting treatment & after dose adjustments. Optimize cortisol replacement therapy prior to treatment. Signs of relapse of malignant disease. Slipped epiphyses of the hip may occur. Discontinue if papilloedema develops & consider diagnosis of benign intracranial HTN, if signs of upper airway obstruction (onset of or increased snoring) develops, & at renal transplantation. Patients w/ PWS should be evaluated for upper airway obstruction sleep apnoea or resp infections before starting treatment. Monitor for scoliosis. Measure fasting insulin & blood glucose annually & IGF-1 twice a year, prior to treatment in SGA childn. SGA patients near onset of puberty. Maintain control of acidosis, hyperparathyroidism & nutritional status for renal insufficiency during treatment. Acute critically ill patients. Pregnancy & lactation.
Adverse Reactions
Formation of antibodies; paraesthesia (adults), stiffness in extremities (adults), arthalgia, myalgia, peripheral oedema, transient local skin reactions at the inj site.
Drug Interactions
May inhibit growth-promoting effects w/ glucocorticoids.
ATC Classification
H01AC01 - somatropin ; Belongs to the class of somatropin and somatropin agonists. Used in anterior pituitary lobe hormone and analogue preparations.
Scitropin A inj soln 5 mg/1.5 mL (15 IU)
Scitropin A inj soln 10 mg/1.5 mL (30 IU)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in